Chemical industry – Page 93
-
Business
Schiff seals deal with Reckitt
Boards approves $1.4 billion Reckitt offer as Bayer pulls out of running
-
BusinessCan the UK fund CCS?
EU is offering €1.5 billion in funding but lack of co-ordination with UK scheme threatens participation
-
BusinessRecord insider trading case hits pharma
US authorities claim that hedge fund manager made illicit gains of $276 million in response to confidential clinical trial data
-
Business
BASF bids €664m for omega-3 company
Pronova BioPharma makes pharmaceutical ingredients as well as nutritional supplements based in omega-3 fatty acids
-
Business
Reckitt steps into Schiff deal
Higher bid could sink Bayer’s $1.2bn attempt to buy vitamins and nutritional supplements company
-
Business
BP to pay £4.5 billion for disaster
Company will plead guilty to criminal charges including felony manslaughter
-
BusinessWhat lies within
Bayer boss Marijn Dekkers aims to increase impact of good R&D across different internal units
-
BusinessObama re-election worries chemical industry
A second term could mean more aggressive environmental regulations and an emboldened EPA, chemical industry groups warn
-
Business
DSM buys food ingredients firm
$634 million deal for Fortitech will expand ‘value chain presence’
-
Business
Takeda buys Envoy for $140m
The small US biotech will boost Takeda’s drug discovery efforts
-
Business
Approval for first gene therapy drug
Glybera (alipogene tiparvovec) injections have been approved in Europe
-
Business
Panel delivers final PFOA report
Probable link between perfluorooctanoic acid, used by DuPont to make fluoro-polymers, and high cholesterol
-
Business
Novartis biotech plant for Singapore
Firm will invest $500 million in biotech manafacturing
-
Opinion
High finance meets big pharma?
Derek Lowe examines an alternative funding model for pharmaceutical research
-
BusinessChemists contribute to prior art hunt
A crowdsourcing website that pays for prior art is gaining popularity – can chemists make money?
-
Business
More jobs go: Lonza cuts 500
A bid to ‘secure the future’ of the site at Visp in Switzerland
-
Business
Patent woes lead to sharp sales losses
Bristol-Myers Squibb, AstraZeneca and Eli Lilly have all suffered loss of exclusivity for key drugs